(HealthDay News) — The U.S. Food and Drug Administration has approved Penmenvy (Meningococcal Groups A, B, C, W, and Y Vaccine) for active immunization against invasive meningococcal disease (IMD), ...

The U.S. Food and Drug Administration approved British drugmaker GSK's combination vaccine to protect against meningococcal ...

The FDA approved GSK’s pentavalent meningococcal vaccine to protect children and young adults aged 10 to 25 years against ...

GSK’s MenABCWY vaccine is an injectable suspension intended for intramuscular use. It comes with a vial of lyophilised ...

Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to ...

The story has been updated to correct the FDA approval date to Friday, February 14 On Friday, February 14, the FDA approved ...

Meningococcal Vaccine MarketThe global meningococcal vaccine market is experiencing significant growth, driven by rising ...

GSK's Penmenvy wins FDA approval to protect against five meningococcal serogroups. The CDC panel will vote on usage ...

Penmenvy combines the antigenic components of Bexsero (meningococcal Group B vaccine) and Menveo (meningococcal Groups A, C, Y, and W-135 oligosaccharide diphtheria CRM197 conjugate vaccine).

Thousands of U.S. health agency employees were terminated and told it was for poor performance, though they'd received strong ...

A panel of experts advising the U.S. Centers for Disease Control and Prevention on vaccines will not convene for its February ...